| Ytd | -70.29% | |
| 1y | -86.85% |
| Open | 0.96 | Prev Close | 0.96 | Low | 0.94 | High | 0.99 | Mkt Cap | 2.90M |
| Vol | 47.76K | Avg Vol | 1.36M | EPS | -7.47 | P/E | N/A | Forward P/E | -0.37 |
| Beta | 1.06 | Short Ratio | 0.02 | Inst. Own | 6.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.19 | 200-d Avg | 2.60 | 1yr Est | 12.00 |
PRFX News
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular
First-Half 2026 and Recent Highlights:Raised $10 million through the Company's equity line facil
Battery-to-Revenue Intelligence is a new capability designed to extend the platform’s optimization w
The validation applied real-world historical weather data, renewable energy production records and m
PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF" or the "Company"), a clinical-stage spec
On June 18, 2026, PRF Technologies Ltd. (the "Company") entered into a Standby Equity Purcha
HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open
PRF Technologies (NASDAQ:PRFX) stock falls sharply Monday morning. Read why analysts see this as a m
Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce
Dell beats massive estimates, IBM launches $5B Project Lightwell, CrowdStrike expands cyber insuranc
Dell Technologies Inc. (DELL) stock rises 38.7% in premarket trading after strong fiscal Q1 sales an
PRF Technologies Ltd. shares surged 186.22% in after-hours trading after advancing its AI-driven ene
PRF-110 is a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine desi
PRF Technologies gains FDA IND clearance for OcuRing-K, advancing Phase 2 trial plans for drop-less
PRF Technologies outlines 2025 progress, with OcuRing-K ocular drug-delivery advancement and AI sola
